Phase II Study of the combination of Elotuzumab with Lenalidomide as Maintenance Therapy post Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Trial Profile

Phase II Study of the combination of Elotuzumab with Lenalidomide as Maintenance Therapy post Autologous Stem Cell Transplant in Patients with Multiple Myeloma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Elotuzumab (Primary) ; Lenalidomide (Primary) ; Dexamethasone; Diphenhydramine; Famotidine
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 May 2017 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
    • 26 May 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
    • 15 Apr 2016 Change in Elotuzumab dosing: earlier it was given on day 1 and 15 after the 2nd cycle, now it is given only on day 1 and planned Patient number increased from 48 to 100.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top